JPRN-jRCTs051200054已完成未知
Efficacy of adjunctive therapy of zonisamide versus increased dose of levodopa for motor symptom in DLB parkinsonism : a randomized, controlled, non-inferiority study. - DUE
Ikeda Manabu0 个研究点目标入组 130 人开始时间: 2020年9月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 < 90age old（—）
- 性别
- All
入选标准
- •At the start of the observation period (Visit 1) and before the start of the evaluation period (Visit 2), patients with dementia with Lewy bodies (DLB) parkinsonism who are receiving levodopa treatment at 300 mg/day or lower and still have Parkinsonism which requires further treatment, are eligible for this study if they meet all of the following criteria.
- •1) Written voluntary informed consent is obtained from the patient and legal representative after a full explanation and understanding of the objectives and nature of this study, expected efficacy/pharmacological action, risk, and other information*
- •- In principle, consent from the patient is required, but if it is difficult to obtain the consent from the patient who is objectively judged to lack the ability of giving informed consent, etc., assent is obtained from the patient with written consent of legal representative.
- •2) Diagnosed with probable DLB according to the revised criteria for clinical diagnosis of DLB (among the core clinical features, onset of parkinsonism is essential)*
- •3) Aged 50 years or older and younger than 90 years at the time of informed consent*
- •4) Outpatients
- •5) (Possibly have remained Parkinsonism which requires further treatment) A total score of 20 or higher on Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
- •6) Their caregivers meeting all of the following criteria*
- •- Witten agreement to cooperate with this study is obtained
- •- Able to provide patient information and drug management required for this study (the caregiver may live together with the patient or separately)
- •- Able to accompany the patient to site visits throughout the study
- •7) Continuously taking levodopa preparations initiated at or before the start of the observation period (Visit 1), on a stable dose of 300 or lower mg/day throughout the observation period**
- •8) History of hallucination or delusion
- •- Including hallucination or delusion present at eligibility assessment
- •9) A stable dose of any antidementia drug, if being used, throughout the observation period**
- •10) Use of the following drugs (restricted concomitant drugs) on a stable dose from 2 weeks before the start of the study treatment (Day 1)**
- •- Other drugs that might affect evaluation (e.g., antihypertensives, central nervous system agents, cardiovascular agents, digestive organ agents, and traditional Chinese medicines)
- •*: Matters only to be checked at the start of the observation period (Visit 1)
- •**: Matters only to be checked before the start of the evaluation period (Visit 2)
排除标准
- •Patients who meet any of the following criteria are excluded from this study.
- •1) Patients with non-DLB parkinsonism (e.g., drug - induced parkinsonism)
- •2) Patients with Parkinson's disease associated with dementia (Parkinson's disease dementia[ PDD]patients)
- •PDD patients: those with parkinsonism occurring 1 year or longer before onset of dementia
- •3) A total score of less than 10 on the Mini-mental State Examination (MMSE)
- •4) Concomitant epilepsy
- •5) Taking any antiparkinsonian drug (including Stalevo [levodopa/carbidopa hydrate/entacapone] and droxidopa) other than levodopa preparations
- •6) Taking any benzamide antipsychotic (sulpiride, sultopride, tiapride, or nemonapride)
- •7) Taking any non-quetiapine antipsychotic
- •8) Taking any metoclopramide preparation
- •9) Taking nicergoline
- •10) Previous intake of zonisamide
- •11) Previous surgical treatment for parkinsonism such as stereotaxy
- •12) Ineligible for this study in the opinion of the investigator because of severe phychiatric symptoms such as confusion, hallucination, delusion, and abnormal behaviors
- •13) Any serious concomitant disease which qualifies as Grade 3 as defined by the Criteria for Seriousness Classification of Adverse Drug Reactions*
- •14) History of any serious liver disease which qualifies as Grade 3 as defined by the Criteria for Seriousness Classification of Adverse Drug Reactions
- •15) History of malignant syndrome
- •16) Concomitant cancer or history of cancer within 5 years before the start of this study
- •17) Pregnant women, patients who may possibly be pregnant, patients who may become pregnant by themselves or their partners without using proper contraceptive measures, patients who plan to become pregnant (including providing sperm to a third party or freezing sperm etc.) or lactating mothers
- •18) Planned participation during the observation period of this study or concomitant participation in another clinical study, post-marketing clinical study, or any other interventional clinical research
- •19) Otherwise ineligible for this study in the opinion of the investigator or subinvestigator
- •* Grade 3 as defined by the Criteria for Seriousness Classification of Adverse Drug Reactions: adverse drug reaction considered serious, which may be fatal or has the risk of causing permanent dysfunction that hinders daily living depending on the patient's predisposition or condition when the event is observed.
研究者
相似试验
终止
3 期
A double blind, randomised, placebo-controlled, mulitcentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures.Neurological - EpilepsyepilepsyACTRN12608000096358Eisia G.C.D., Eisai Ltd.154
进行中（未招募）
2 期
Study on efficacy and safety of zonisamide in at-risk subjects of Lewy body diseaseJPRN-jRCTs041190126Katsuno Masahisa30
进行中（未招募）
1 期
A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated EpilepsiesEpilepsyEUCTR2016-004955-64-Outside-EU/EEAEisai Korea Inc.133
已完成
4 期
A Clinical Trial to evaluate the safety and efficacy of zonisamide an antiepileptic drug in treatment patients with seizures (Fits). This is a postmarketing study to further confirm the safety and efficacy in large number of patients in the approved types of seizures.CTRI/2010/091/002925Eisai Pharmaceuticals India Private Limited.1st Floor, B-Wing, Marwah Centre, Krishanlal Marwah Marg, Andheri East, Mumbai - 400072655
已完成
不适用
Effect of Zonisamide and Pregabalin in control of interactable epilepsy in childreInteractable epilepsy.Episodic and paroxysmal disordersIRCT2012091210508N4Shahid Beheshti University of Medical Science96